R&D tag:www.umnpharma.com,2009-03-13:/en/product_pipeline//7 2009-06-20T07:06:09Z Movable Type Commercial 4.24-ja UMN-0501 tag:www.umnpharma.com,2009:/en/product_pipeline//7.95 2009-04-06T00:47:22Z 2009-06-20T07:06:09Z UMN-0501 is a pandemic influenza vaccine... 管理者 UMN-0501 is a pandemic influenza vaccine manufactured in insect cells through the use of recombinant DNA technology. UMN-0501 represents the most advanced cell-based pandemic influenza vaccine in the world. A cell-based influenza vaccine offers key advantages over influenza vaccines manufactured using older production methods such as speed, safety and cost effectiveness. Phase I/II clinical trials have been successfully completed with both immunogenicity and safety confirmed. Results were presented in February of 2008 at the World Health Organization's 5th Meeting on Evaluation of Pandemic Influenza Prototype Vaccines in Clinical Trials. The next step in development will be a Phase II/III clinical trial to confirm UMN-0501's safety and efficacy as a pre-pandemic vaccine. UMN-0501 was granted orphan drug status in May of 2008. UMN's influenza program was licensed from Protein Sciences Corporation in the United States. Under this agreement, UMN Pharma secured exclusive development, manufacturing and sales rights in Japan to Protein Sciences proprietary influenza program and related technology. UMN-0502 tag:www.umnpharma.com,2009:/en/product_pipeline//7.94 2009-04-06T00:45:48Z 2010-08-20T02:59:14Z UMN-0502 is seasonal influenza vaccine m... 管理者 UMN-0502 is seasonal influenza vaccine manufactured in insect cells through the use of recombinant DNA technology. Protein Sciences Corporation is developing a novel seasonal influenza candidate in the United States called FluBlok. FluBlok has successfully completed Phase III clinical trials and is awaiting formal marketing approval from the Food and Drug Administration.　UMN Pharma has completed a successful meeting with PMDA regarding future clinical trials. UMN-03 tag:www.umnpharma.com,2009:/en/product_pipeline//7.20 2009-03-24T08:30:44Z 2009-06-20T07:15:07Z UMN-03 is a fusion protein being develo... 管理者
UMN-03 is a fusion protein being developed for myogenic and neurogenic diseases with a novel mode of action which was discovered at the University of Tokushima. The target of this biological drug candidate is so-called myostatin. Substantial published data indicate that blocking the action of myostatin can promote extra muscle growth, thus providing potential therapeutic advantage for patients with congenital intractable myopathy such as Duchenne muscular dystrophy(DMD). Furthermore, UMN-03 can reduce fat tissue and could thereby provide a new therapeutic approach for type II diabetes or obesity. We are currently negotiating with several pharmaceutical companies both domestically and internationally.
]]>